OncLive TV

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Maha Hussain, MD, FACP, FASCO, discusses the design of the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer.

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.

Nicole Concin, MD, discusses the patient population that enrolled in the phase ​1b/2 LIO-1 trial in advanced gynecologic malignancies.

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma. 

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Ziad Bakouny, MD, MSc, discusses the rate of disease progression in sarcomatoid carcinoma.

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Seema A. Bhat, MD, discusses the rationale to evaluate acalabrutinib in chronic lymphocytic leukemia.

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the next steps of the phase 3 DASL-HiCAP trial in high-risk prostate cancer.

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

William W. Tseng, MD, discusses the significance of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group analysis in retroperitoneal sarcoma.

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

David H. Vesole, MD, PhD, discusses the importance of developing off-the-shelf CAR T-cell therapy ​products in multiple myeloma.

Matthew S. Davids, MD, MMSc, discusses factors to consider when selecting treatment for patients with chronic lymphocytic leukemia.

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Gina Z. D'Amato, MD, discusses the diminishing role of chemotherapy in sarcoma.